<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009086</url>
  </required_header>
  <id_info>
    <org_study_id>CR016315</org_study_id>
    <secondary_id>CNTO1275PSA3001</secondary_id>
    <secondary_id>2009-012264-14</secondary_id>
    <nct_id>NCT01009086</nct_id>
    <nct_alias>NCT01902706</nct_alias>
  </id_info>
  <brief_title>A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness (improvement of signs and
      symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (participants are assigned different treatments based on chance),
      double-blind (neither the participant nor the physician knows whether drug or placebo is
      being taken, or at what dosage), parallel-group (each group of participants will be treated
      at the same time), and multicenter (study conducted at multiple sites) study. Approximately,
      615 participants will participate in this study. Participants will be assigned to one of
      three treatment groups: Group I: ustekinumab 45 mg, Group II: ustekinumab 90 mg, and Group
      III: placebo group (an inactive substance). Participants will receive either 45 mg
      ustekinumab or 90 mg ustekinumab at Weeks 0, 4, and every 12 weeks until Week 88 as
      randomized to respective groups. Participants in placebo group will receive placebo at Weeks
      0, 4, 16, and 20 and 45 mg ustekinumab at Weeks 24 and 28 followed by every 12 weeks dosing
      until Week 88. Participants who do not have greater than or equal to 5 percentage improvement
      in their disease (tender and swollen joints) will be eligible for an early escape.
      Specifically, during early escape at Week 16, participants in Group I will receive 90 mg
      ustekinumab, for participants in Group II same dosing schedule will be continued, and
      participants in placebo group will receive 45 mg ustekinumab. Safety evaluations will include
      assessments of adverse events, clinical laboratory tests, and physical examination. The
      maximum study duration will be approximately 108 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 20 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 centimeters [cm]) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in the Disability Index Score as Measured With the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI)</measure>
    <time_frame>Day 1 (Baseline) and Week 24</time_frame>
    <description>The HAQ-DI is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ-DI score which ranges from 0 (no disability) to 3 (completely disabled). In psoriatic arthritis, a decrease in score of 0.30 indicates clinically meaningful improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (With &gt;= 3% Baseline Body Surface Area (BSA) Psoriatic Involvement) Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The PASI is a physician-administered assessment tool used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A PASI 75 response is defined as greater than or equal to 75 percent improvement in PASI score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 50 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4)Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>An ACR 70 response is defined as a greater than or equal to 70 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 70 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Total Modified Van Der Heijde-Sharp (vdH-S) Score for the Combined Radiographic Data From Studies CNTO1275PSA3001 and CNTO1275PSA3002</measure>
    <time_frame>Day 1 (Baseline) and Week 24</time_frame>
    <description>The modified vdH-S score is a radiographic evaluation of hand and feet erosions and joint space narrowing (JSN) for 20 joints per hand and 6 joints per foot with a total score ranging from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score and positive score changes indicate more radiographic damage and radiographic progression, respectively. As per protocol, analysis for this outcome measure used pooled data from 2 studies (CNTO1275PSA3001 and PSA3002) because initial power assumptions showed that 900 participants would be required to evaluate impact of ustekinumab on structural damage (SD) progression. The 2 studies, (which had similar study designs and dosing regimens with difference to prior exposure to anti-tumor necrosis factor alpha (TNFÎ±) therapies), were intended to independently measure efficacy in terms of signs, symptoms and physical function, while effects on SD progression is provided from an integrated analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC injections</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ustekinumab 45 mg</arm_group_label>
    <arm_group_label>Ustekinumab 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 45 mg</intervention_name>
    <description>SC injections</description>
    <arm_group_label>Ustekinumab 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 90 mg</intervention_name>
    <description>SC injections</description>
    <arm_group_label>Ustekinumab 45 mg</arm_group_label>
    <arm_group_label>Ustekinumab 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had a documented diagnosis of psoriatic arthritis (PsA) at least 6 months

          -  Have a diagnosis of active PsA at the time of entry into the study

          -  If the participant is using methotrexate they should have started treatment at a dose
             not to exceed 25 milligram per week at least 3 months prior to the beginning of the
             study and should have no serious toxic side effects attributable to methotrexate.
             Methotrexate route of administration and doses should be stable for at least 4 weeks
             prior to the first administration of study agent. If currently not using methotrexate,
             must have not received methotrexate for at least 4 weeks prior to the first
             administration of the study agent

        Exclusion Criteria:

          -  Have other inflammatory diseases, including but not limited to rheumatoid arthritis,
             ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease

          -  Have used any therapeutic agent targeted at reducing interleukin (IL)-12 or IL-23,
             including but not limited to ustekinumab and briakinumab (ABT-874)

          -  Have used any biologic agents that are targeted for reducing tumor necrosis
             factor-alpha, including but not limited to infliximab, etanercept, adalimumab, and
             golimumab

          -  Have a medical history of latent or active granulomatous infection

          -  Have any known malignancy or have a history of malignancy (with the exception of basal
             cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in
             situ that has been treated with no evidence of recurrence, or squamous cell carcinoma
             of the skin that has been treated with no evidence of recurrence within 5 years of the
             beginning of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroochydore</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien N/A</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Catherines</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>HyvinkÃ¤Ã¤</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>TÃ¼bingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest N/A</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>KecskemÃ©t</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>VeszprÃ©m</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>BiaÅystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Korolev</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-On-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <results_first_submitted>October 11, 2013</results_first_submitted>
  <results_first_submitted_qc>January 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2014</results_first_posted>
  <disposition_first_submitted>October 16, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 18, 2012</disposition_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis, Psoriatic</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>CNTO 1275</keyword>
  <keyword>Stelara</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: PLACEBO</title>
          <description>Placebo Subcutaneous (SC) injections at Weeks 0, 4, 16 and 20. If Early Escape then participants would receive Ustekinumab 45 mg injections starting Week 16 with the last dose at Week 88. If Crossover then participants would receive Ustekinumab 45 milligram (mg) injections starting Week 24 with the last dose at Week 88.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: USTEKINUMAB 45 MG</title>
          <description>Ustekinumab Subcutaneous (SC) injections of 45 mg starting at Week 0 with the last dose at Week 88. If Early Escape then participants would receive Ustekinumab 90 mg injections starting Week 16 with the last dose at Week 88.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: USTEKINUMAB 90 MG</title>
          <description>Ustekinumab Subcutaneous (SC) injections of 90 mg starting at Week 0 with the last dose at Week 88.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: PLACEBO</title>
          <description>Placebo Subcutaneous (SC) injections at Weeks 0, 4, 16 and 20. If Early Escape then participants would receive Ustekinumab 45 mg injections starting Week 16 with the last dose at Week 88. If Crossover then participants would receive Ustekinumab 45 milligram (mg) injections starting Week 24 with the last dose at Week 88.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: USTEKINUMAB 45 MG</title>
          <description>Ustekinumab Subcutaneous (SC) injections of 45 mg starting at Week 0 with the last dose at Week 88. If Early Escape then participants would receive Ustekinumab 90 mg injections starting Week 16 with the last dose at Week 88.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: USTEKINUMAB 90 MG</title>
          <description>Ustekinumab Subcutaneous (SC) injections of 90 mg starting at Week 0 with the last dose at Week 88.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="204"/>
            <count group_id="B4" value="615"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="12.29"/>
                    <measurement group_id="B2" value="47.1" spread="12.64"/>
                    <measurement group_id="B3" value="46.8" spread="11.75"/>
                    <measurement group_id="B4" value="47.1" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.</title>
        <description>An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 20 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 centimeters [cm]) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
        <time_frame>Week 24</time_frame>
        <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.</title>
          <description>An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 20 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 centimeters [cm]) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
          <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="49.5"/>
                    <measurement group_id="O4" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in the Disability Index Score as Measured With the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI)</title>
        <description>The HAQ-DI is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ-DI score which ranges from 0 (no disability) to 3 (completely disabled). In psoriatic arthritis, a decrease in score of 0.30 indicates clinically meaningful improvement.</description>
        <time_frame>Day 1 (Baseline) and Week 24</time_frame>
        <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in the Disability Index Score as Measured With the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI)</title>
          <description>The HAQ-DI is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ-DI score which ranges from 0 (no disability) to 3 (completely disabled). In psoriatic arthritis, a decrease in score of 0.30 indicates clinically meaningful improvement.</description>
          <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.390"/>
                    <measurement group_id="O2" value="-0.31" spread="0.521"/>
                    <measurement group_id="O3" value="-0.40" spread="0.514"/>
                    <measurement group_id="O4" value="-0.36" spread="0.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants (With &gt;= 3% Baseline Body Surface Area (BSA) Psoriatic Involvement) Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24</title>
        <description>The PASI is a physician-administered assessment tool used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A PASI 75 response is defined as greater than or equal to 75 percent improvement in PASI score from baseline.</description>
        <time_frame>Week 24</time_frame>
        <population>All participants randomly assigned to a treatment group, regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24. Only participants with &gt;=3% baseline BSA psoriatic involvement were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants (With &gt;= 3% Baseline Body Surface Area (BSA) Psoriatic Involvement) Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24</title>
          <description>The PASI is a physician-administered assessment tool used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A PASI 75 response is defined as greater than or equal to 75 percent improvement in PASI score from baseline.</description>
          <population>All participants randomly assigned to a treatment group, regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24. Only participants with &gt;=3% baseline BSA psoriatic involvement were included in this analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="57.2"/>
                    <measurement group_id="O3" value="62.4"/>
                    <measurement group_id="O4" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24</title>
        <description>An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 50 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4)Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
        <time_frame>Week 24</time_frame>
        <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24</title>
          <description>An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 50 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4)Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
          <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="24.9"/>
                    <measurement group_id="O3" value="27.9"/>
                    <measurement group_id="O4" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Week 24</title>
        <description>An ACR 70 response is defined as a greater than or equal to 70 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 70 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
        <time_frame>Week 24</time_frame>
        <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Week 24</title>
          <description>An ACR 70 response is defined as a greater than or equal to 70 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 70 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4) Participant's assessment of physical function as measured by the &quot;Disability Index of the Health Assessment Questionnaire&quot; (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.</description>
          <population>All participants randomly assigned to a treatment group were included in the efficacy analysis regardless of whether they received the assigned treatment. For early escape, data at or prior to Week 16 were carried forward through Week 24.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="14.2"/>
                    <measurement group_id="O4" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Total Modified Van Der Heijde-Sharp (vdH-S) Score for the Combined Radiographic Data From Studies CNTO1275PSA3001 and CNTO1275PSA3002</title>
        <description>The modified vdH-S score is a radiographic evaluation of hand and feet erosions and joint space narrowing (JSN) for 20 joints per hand and 6 joints per foot with a total score ranging from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score and positive score changes indicate more radiographic damage and radiographic progression, respectively. As per protocol, analysis for this outcome measure used pooled data from 2 studies (CNTO1275PSA3001 and PSA3002) because initial power assumptions showed that 900 participants would be required to evaluate impact of ustekinumab on structural damage (SD) progression. The 2 studies, (which had similar study designs and dosing regimens with difference to prior exposure to anti-tumor necrosis factor alpha (TNFÎ±) therapies), were intended to independently measure efficacy in terms of signs, symptoms and physical function, while effects on SD progression is provided from an integrated analysis.</description>
        <time_frame>Day 1 (Baseline) and Week 24</time_frame>
        <population>Analysis included: (1) combined data from studies CNTO1275PSA3001 (NCT01009086) and CNTO1275PSA3002 (NCT01077362) and (2) all participants randomly assigned to a treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received subcutaneous injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants crossed over to receive subcutaneous injections of ustekinumab 45 milligram (mg) at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 45 mg ustekinumab were given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a subcutaneous placebo injection was given at Week 24 to maintain the blind.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 45 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, subcutaneous injections of 90 mg ustekinumab were given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg</title>
            <description>Participants received subcutaneous injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. Participants received subcutaneous injections of placebo at Weeks 20 and 24 to maintain the blind.</description>
          </group>
          <group group_id="O4">
            <title>All Ustekinumab Combined</title>
            <description>Participants who received subcutaneous injections of ustekinumab at any dose (45 mg and 90 mg) through Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Total Modified Van Der Heijde-Sharp (vdH-S) Score for the Combined Radiographic Data From Studies CNTO1275PSA3001 and CNTO1275PSA3002</title>
          <description>The modified vdH-S score is a radiographic evaluation of hand and feet erosions and joint space narrowing (JSN) for 20 joints per hand and 6 joints per foot with a total score ranging from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score and positive score changes indicate more radiographic damage and radiographic progression, respectively. As per protocol, analysis for this outcome measure used pooled data from 2 studies (CNTO1275PSA3001 and PSA3002) because initial power assumptions showed that 900 participants would be required to evaluate impact of ustekinumab on structural damage (SD) progression. The 2 studies, (which had similar study designs and dosing regimens with difference to prior exposure to anti-tumor necrosis factor alpha (TNFÎ±) therapies), were intended to independently measure efficacy in terms of signs, symptoms and physical function, while effects on SD progression is provided from an integrated analysis.</description>
          <population>Analysis included: (1) combined data from studies CNTO1275PSA3001 (NCT01009086) and CNTO1275PSA3002 (NCT01077362) and (2) all participants randomly assigned to a treatment group.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="617"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="3.852"/>
                    <measurement group_id="O2" value="0.40" spread="2.110"/>
                    <measurement group_id="O3" value="0.39" spread="2.403"/>
                    <measurement group_id="O4" value="0.40" spread="2.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>re-randomization test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 108</time_frame>
      <desc>Safety population included all participants who received the investigational drug and had safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-16) - Placebo group. Placebo Subcutaneous (SC) injections will be received at Weeks 0, 4 and 16.</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-16) - Ustekinumab 45 mg group. Participants received SC injections of ustekinumab 45 mg at Weeks 0 and 4 and 16.</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-16) - Ustekinumab 90 mg group. Participants received SC injections of ustekinumab 90 mg at Weeks 0 and 4 and 16.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (After CP)</title>
          <description>After Controlled period (Week 16-24) â participants receiving placebo at Weeks 0, 4, 16, and 20, then crossed over to ustekinumab 45 mg at Week 24.</description>
        </group>
        <group group_id="E5">
          <title>Placebo -&gt; Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 16-108) â participants randomized to placebo who early escaped to ustekinumab 45 mg at Week 16 or who crossed over to ustekinumab 45 mg at Week 24.</description>
        </group>
        <group group_id="E6">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 16-108) â participants randomized to ustekinumab 45 mg at Week 0, irrespective of their early escape status.</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 16-108) â participants randomized to ustekinumab 90 mg at Week 0, irrespective of their early escape status.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Chronic Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pneumonia Mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Proteus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Finger Deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Osteoporotic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="57" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

